Volume 9 Supplement 2
Initial surveillance of suspected undesirable drug reactions to some Artemisinin-based combination therapies (ACTs) in Lagos, Nigeria
© Afolabi et al; licensee BioMed Central Ltd. 2010
Published: 20 October 2010
The exacerbation of malaria in sub-Saharan Africa towards the end of the 20th century accrued from amplified resistance to chloroquine and sulfadoxine-pyrimethamine (SP) the most affordable antimalaria medicines . Contact with substandard antimalarial medicines probably aggravated this development [2–4]. Pressure from malaria scientists triggered extensive acceptance and implementation of artemisinin-based combination therapies (ACTs) by endemic country governments and donors . All medicines carry some risk of harm and it is important to monitor their intended and unwanted effects for good evidence upon which to base an assessment of risk versus effectiveness or risk versus benefit. Furthermore, particularly with new medicines, the early identification of unexpected adverse reactions and their risk factors is essential, so that the medicines can be used in an informed manner with the least chance of harm. This is the role of pharmacovigilance (PV). Information gathered during pharmacovigilance may also assist in selecting the most appropriate medicine for future use. The objectives of this study were to document the suspected undesirable but common adverse drug reactions (SADRs) of patients using various Artemisinin-based Combination therapies (ACTs) in Lagos, (Nigeria) and to document the involvement of community pharmacists in the detection and reporting of these ADRs.
Materials and methods
A semi-structured questionnaire was served to each of the 235 randomly selected community pharmacists/respondents in urban and semi-urban Lagos metropolis between May and July 2008 out of which 201 (83.8%) responded.
Proportion of patients with suspected adverse drug reactions (SADRs) to various Artemisinin-based combination therapies (ACT) in Lagos (2008).
Artemisinin Monotherapy (number of reports=410)
Artesunate-Mefloquine (number of reports=521)
Artesunate-Amodiaquine (number of reports=961)
Artemeter-Lumefantrine (number of reports=401)
Dihydro artemisinin/SP (number of reports=642)
Tightening of chest
General body pain
Suspected adverse drug reactions especially to AA are factors that limit its use as an effective ACT which has unpalatable reactions to the patient. The confidence of end users of this particular ACT wanes with the development of suspected but constant mild, moderate to severe adverse drug reactions.
- Gomes M, Wayling S, Pang L: Interventions to improve the use of antimalarials in south-east Asia: an overview. Bull World Health Organ. 1998, 76: 9-19.PubMed CentralPubMedGoogle Scholar
- Minzi OMS, Moshi MJ, Hipolite D, Massele AY, Tomson G: Evaluation of the quality of amodiaquine and sulphadoxine/pyrimethamine tablets sold by private wholesale pharmacies in Dar Es Salaam Tanzania. Journal of Clinical Pharmacy and Therapeutics. 2003, 28: 117-122. 10.1046/j.1365-2710.2003.00470.x.View ArticlePubMedGoogle Scholar
- Amin AA, Snow RW, Kokwaro GO: The quality of sulphadoxinepyrimethamine and amodiaquine products in the Kenyan retail sector. Journal of Clinical Pharmacy and Therapeutics. 2005, 30: 559-565. 10.1111/j.1365-2710.2005.00685.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Basco LK: Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication. Am J Trop Med Hyg. 2004, 70: 245-250.PubMedGoogle Scholar
- Attaran A, Barnes KI, Curtis C, D'Alessandro U, Fanello CI: WHO, the Global Fund and medical malpractice in malaria treatment. The Lancet 363(9404). 2004, 237-240. 10.1016/S0140-6736(03)15330-5.Google Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.